Monitoring response and resistance to the novel arsenical darinaparsin in an AML patient

Frontiers in Pharmacology

Volumn 4 FEB, Issue , 2013, Pages

  Nielsen, Torsten H ^a   Johnson, Nathalie ^a   Garnier, Nicolas ^a   Kwan, Stanley ^a   Yao, Lu ^a   Cocolakis, Eftihia ^a   Hébert, Josée ^b   Morgan, Robert A ^c   Paquet, Eric ^d   Callahan, Kevin P ^e   Jordan, Craig T ^e   Assouline, Sarit ^a   Miller Jr , Wilson H ^a   Mann, Koren K ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c Ziopharm Oncology Inc   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Acute myeloid leukemia; Darinaparsin; Experimental treatment; Inv(3)(q21q26.2); Personalized medicine; Resistance

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DARINAPARSIN; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IDARUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MITOXANTRONE; RIBAVIRIN;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTILEUKEMIC EFFECT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY TEMPERATURE; CASE REPORT; CHROMOSOME INVERSION; CHROMOSOME INVERSION 3; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG RESPONSE; DRUG SCREENING; DRUG TOLERABILITY; EX VIVO STUDY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PATIENT MONITORING; PERSONALIZED MEDICINE; QUALITY OF LIFE; TUMOR XENOGRAFT;

EID: 84881525145     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00009     Document Type: Article

References (14)

1. Buonamici, S., Chakraborty, S., Senyuk, V., and Nucifora, G. (2003). The role of EVI1 in normal and leukemic cells. Blood Cells Mol. Dis. 31, 206-212.
2. Hardin, J. A., Sherr, D. H., DeMaria, M., and Lopez, P. A. (1992). A simple fluorescence method for surface antigen phenotyping of lymphocytes undergoing DNA fragmentation. J. Immunol. Methods 154, 99-107.
3. Kornblau, S. M., McCue, D., Singh, N., Chen, W., Estrov, Z., and Coombes, K. R. (2010). Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood 116, 4251-4261.
4. Lugthart, S., Figueroa, M. E., Bindels, E., Skrabanek, L., Valk, P. J., Li, Y., et al. (2011). Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood 117, 234-241.
5. Lugthart, S., Gröschel, S., Beverloo, H. B., Kayser, S., Valk, P. J., van Zelderen-Bhola, S. L., et al. (2010). Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J. Clin. Oncol. 28, 3890-3898.
6. Mann, K. K., Wallner, B., Lossos, I. S., and Miller, W. H. Jr. (2009). Darinaparsin: a novel organic arsenical with promising anticancer activity. Expert Opin. Investig. Drugs 18, 1727-1734.
7. Matulis, S. M., Morales, A. A., Yehiayan, L., Croutch, C., Gutman, D., Cai, Y., et al. (2009). Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Mol. Cancer Ther. 8, 1197-1206.
8. Raza, A., Buonamici, S., Lisak, L., Tahir, S., Li, D., Imran, M., et al. (2004). Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk. Res. 28, 791-803.
9. Shackelford, D., Kenific, C., Blusztajn, A., Waxman, S., and Ren, R. (2006). Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide. Cancer Res. 66, 11360-11369.
10. Swerdlow, S. H., Campo, E., Harris, N. L., Jaffe, E. S., Pileri, S. A., Stein, H., et al. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press.
11. Tsimberidou, A. M., Camacho, L. H., Verstovsek, S., Ng, C., Hong, D. S., Uehara, C. K., et al. (2009). A phase I clinical trial of darinaparsin in patients with refractory solid tumors. Clin. Cancer Res. 15, 4769-4776.
12. Waugh, D. J., and Wilson, C. (2008). The interleukin-8 pathway in cancer. Clin. Cancer Res. 14, 6735-6741.
13. Yoshimi, A., Goyama, S., Watanabe-Okochi, N., Yoshiki, Y., Nannya, Y., Nitta, E., et al. (2011). Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood 117, 3617-3628.
14. Yuasa, H., Oike, Y., Iwama, A., Nishikata, I., Sugiyama, D., Perkins, A., et al. (2005). Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J. 24, 1976-1987.